Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?
Asthma
Asthma biologics
Immunoregulation
type 2
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
08
03
2023
received:
14
10
2022
accepted:
10
03
2023
medline:
14
8
2023
pubmed:
19
3
2023
entrez:
18
3
2023
Statut:
ppublish
Résumé
Asthma is classically considered to be a disease of type 2 immune dysfunction, since many patients exhibit the consequences of excess secretion of cytokines such as IL-4, IL-5, and IL-13 concomitant with inflammation typified by eosinophils. Mouse and human disease models have determined that many of the canonical pathophysiologic features of asthma may be caused by these disordered type 2 immune pathways. As such considerable efforts have been made to develop specific drugs targeting key cytokines. There are currently available multiple biologic agents that successfully reduce the functions of IL-4, IL-5, and IL-13 in patients, and many improve the course of severe asthma. However, none are curative and do not always minimize the key features of disease, such as airway hyperresponsiveness. Here, we review the current therapeutic landscape targeting type 2 immune cytokines and discuss evidence of efficacy and limitations of their use in adults and children with asthma.
Identifiants
pubmed: 36932669
doi: 10.1002/eji.202249919
doi:
Substances chimiques
Interleukin-13
0
Interleukin-5
0
Interleukin-4
207137-56-2
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2249919Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Tu, L., Chen, J., Zhang, H. and Duan, L., Interleukin-4 inhibits regulatory T cell differentiation through regulating CD103+ dendritic cells. Front. Immunol. 2017. 8: 214.
Palomares, O., Akdis, M., Martin-Fontecha, M. and Akdis, C. A., Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol. Rev. 2017. 278: 219-236.
Coyle, A. J., Le Gros, G., Bertrand, C., Tsuyuki, S., Heusser, C. H., Kopf, M., Anderson, G. P. et al., Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 1995. 13: 54-59.
Tepper, R. I., Levinson, D. A., Stanger, B. Z., Campos-Torres, J., Abbas, A. K. and Leder, P., IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 1990. 62: 457-467.
Fukuda, T., Fukushima, Y., Numao, T., Ando, N., Arima, M., Nakajima, H., Sagara, H. et al., Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am. J. Respir. Cell Mol. Biol. 1996. 14: 84-94.
Dabbagh, K., Takeyama, K., Lee, H. M., Ueki, I. F., Lausier, J. A. and Nadel, J. A., IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J. Immunol. 1999. 162: 6233-6237.
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., Donaldson, D. D. et al., Interleukin-13: central mediator of allergic asthma. Science 1998. 282: 2258-2261.
Leyva-Castillo, J. M., Das, M., Artru, E., Yoon, Y., Galand, C. and Geha, R., Mast cell-derived IL-13 downregulates IL-12 production by skin dendritic cells to inhibit the Th1 response to cutaneous antigen exposure. J. Allergy Clin Immunol. 2021. 147: 2305-2315.
Punnonen, J., Yssel, H. and de Vries, J. E., The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J. Allergy Clin. Immunol. 1997. 100(Pt 1): 792-801.
Junttila, I. S., Mizukami, K., Dickensheets, H., Meier-Schellersheim, M., Yamane, H., Donnelly, R. P., Paul, W E. et al., Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity. J. Exp. Med. 2008. 205: 2595-2608.
Chibana, K., Trudeau, J. B., Mustovich, A. T., Hu, H., Zhao, J., Balzar, S., Chu, H. W. et al., IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin. Exp. Allergy 2008. 38: 936-946.
Zhu, Z., Homer, R. J., Wang, Z., Chen, Q., Geba, G. P., Wang, J., Zhang, Y. et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 1999. 103: 779-788.
Pelaia, C., Paoletti, G., Puggioni, F., Racca, F., Pelaia, G., Canonica, G. W., Heffler, E. et al., Interleukin-5 in the pathophysiology of severe asthma. Front. Physiol. 2019. 10: 1514.
Broide, D. H., Paine, M. M. and Firestein, G. S., Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J. Clin. Invest. 1992. 90: 1414-1424.
Bousquet, J., Chanez, P., Lacoste, J. Y., Barneon, G., Ghavanian, N., Enander, I., Venge, P. et al., Eosinophilic inflammation in asthma. N. Engl. J. Med. 1990. 323: 1033-1039.
Fulkerson, P. C. and Rothenberg, M. E., Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013. 12: 117-129.
Colombo, P. E., Quenet, F., Alric, P., Mourregot, A., Neron, M., Portales, F., Rouanet, P. et al., Distal pancreatectomy with celiac axis resection (modified appleby procedure) and arterial reconstruction for locally advanced pancreatic adenocarcinoma after FOLFIRINOX chemotherapy and chemoradiation therapy. Ann. Surg. Oncol. 2021. 28: 1106-1108.
Simson, L. and Foster, P. S., Chemokine and cytokine cooperativity: eosinophil migration in the asthmatic response. Immunol. Cell Biol. 2000. 78: 415-422.
Rothenberg, M. E. and Hogan, S. P., The eosinophil. Annu. Rev. Immunol. 2006. 24: 147-174.
Roufosse, F., Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne) 2018. 5: 49.
Junttila, I. S., Tuning the cytokine responses: An update on interleukin (IL)-4 and IL-13 receptor complexes. Front. Immunol. 2018. 9: 888.
Borish, L. C., Nelson, H. S., Corren, J., Bensch, G., Busse, W. W., Whitmore, J. B., Agosti, M. et al., Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 2001. 107: 963-970.
Borish, L. C., Nelson, H. S., Lanz, M. J., Claussen, L., Whitmore, J. B., Agosti, J. M., Garrison, L. et al., Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 1999. 160: 1816-1823.
McCormick, S. M. and Heller, N. M., Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015. 75: 38-50.
Campbell, S. M., Knipper, J. A., Ruckerl, D., Finlay, C. M., Logan, N., Minutti, C. M., Mack, M. et al., Myeloid cell recruitment versus local proliferation differentiates susceptibility from resistance to filarial infection. Elife 2018. 7: e30947.
Liu, Q., Yu, Z., Tian, F., Zhao, J., Zhang, H., Zhai, Q., Chen, W. et al., Surface components and metabolites of probiotics for regulation of intestinal epithelial barrier. Microb. Cell Fact. 2020. 19: 23.
Tavernier, J., Devos, R., Cornelis, S., Tuypens, T., Van der Heyden, J., Fiers, W., Plaetinck, G. et al., A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991. 66: 1175-1184.
Walford, H. H. and Doherty, T. A., STAT6 and lung inflammation. JAKSTAT 2013. 2: e25301.
Gour, N. and Wills-Karp, M., IL-4 and IL-13 signaling in allergic airway disease. Cytokine 2015. 75: 68-78.
Munitz, A., Brandt, E. B., Mingler, M., Finkelman, F. D. and Rothenberg, M. E., Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 2008. 105: 7240-7245.
Kuperman, D., Schofield, B., Wills-Karp, M. and Grusby, M. J., Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J. Exp. Med. 1998. 187: 939-948.
Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M. and Geba, G. P., Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy 2012. 42: 712-737.
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H. et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012. 380: 651-659.
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M et al., Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 2011. 365: 1088-1098.
Reddel, H. K., Reply: About the recommendation of the GINA strategy report on asthma step 1. Eur. Respir. J. 2021. 57: 2004226.
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M. et al., Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014. 371: 1198-1207.
Castro, M., Zangrilli, J. and Wechsler, M.E., Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015. 3: e15.
Chupp, G. L., Bradford, E. S., Albers, F. C., Bratton, D. J., Wang-Jairaj, J., Nelsen, L. M., Trevor, J. L. et al., Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017. 5: 390-400.
Hearn, A. P., Kavanagh, J., Ancona, d' G., Roxas, C., Green, L., Thomson, L., Fernandes, M. et al., The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J. Allergy Clin. Immunol.: Pract. 2021. 9: 2093-2096 e1.
Laviolette, M., Gossage, D. L., Gauvreau, G., Leigh, R., Olivenstein, R., Katial, R., Busse, W W. et al., Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 2013. 132: 1086-1096 e5.
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T. et al., Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016. 388: 2128-2141.
Bleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S. et al., Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016. 388: 2115-2127.
Busse, W. W., Bleecker, E. R., FitzGerald, J. M., Ferguson, G. T., Barker, P., Sproule, S., Olsson, R. F. et al., Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 2019. 7: 46-59.
Kavanagh, J. E., Hearn, A. P., Dhariwal, J., Ancona, d' G., Douiri, A., Roxas, C., Fernandes, M. et al., Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest 2021. 159: 496-506.
Lugogo, N. L., Kreindler, J. L., Martin, U. J., Cook, B., Hirsch, I. and Trudo, F. J., Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann. Allergy Asthma Immunol. 2020. 125: 171-176.
Betancor, D., Olaguibel, J. M., Rodrigo-Munoz, J. M., Arismendi, E., Barranco, P., Barroso, B. et al., How reliably can algorithms identify eosinophilic asthma phenotypes using non-invasive biomarkers? Clin. Transl. Allergy 2022. 12: e12182.
Korevaar, D. A., Westerhof, G. A., Wang, J., Cohen, J. F., Spijker, R., Sterk, P. J., Bel, E. H. et al., Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir. Med. 2015. 3: 290-300.
Hanania, N. A., Korenblat, P., Chapman, K. R., Bateman, E. D., Kopecky, P., Paggiaro, P., Yokoyama, A. et al., Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016. 4: 781-796.
Brightling, C. E., Chanez, P., Leigh, R., O'Byrne, P. M., Korn, S., She, D., May, R. D. et al., Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2015. 3: 692-701.
Panettieri R. A., Jr., Sjobring, U., Peterffy, A., Wessman, P., Bowen, K., Piper, E., Colice, G. et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir. Med. 2018. 6: 511-525.
Nair, P. and O'Byrne, P. M., The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. Eur. Respir. J. 2019. 53: 1802250.
Dunican, E. M., Elicker, B. M., Gierada, D. S., Nagle, S. K., Schiebler, M. L., Newell, J. D., Raymond, W. W. et al., Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J. Clin. Invest. 2018. 128: 997-1009.
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W W. et al., Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 2018. 378: 2486-2496.
Castro, M., Rabe, K. F., Corren, J., Pavord, I. D., Katelaris, C. H., Tohda, Y., Zhang, B. et al., Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res 2020. 6: 00204-2019.
Menzies-Gow, A., Mansur, A. H. and Brightling, C. E., Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur. Respir. J. 2020. 55: 1901633.
Caminati, M., Olivieri, B., Dama, A., Micheletto, C., Paggiaro, P., Pinter, P., Senna, G. et al., Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev. Respir. Med. 2022. 16: 713-721.
Gauvreau, G. M., Sehmi, R., Ambrose, C. S. and Griffiths, J. M., Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin. Ther. Targets 2020. 24: 777-792.
Corren, J., Parnes, J. R., Wang, L., Mo, M., Roseti, S. L., Griffiths, J. M., van der Merwe, R., Tezepelumab in adults with uncontrolled asthma. N. Engl. J. Med. 2017. 377: 936-946.
Menzies-Gow, A., Corren, J., Bourdin, A., Chupp, G., Israel, E., Wechsler, M. E., Brightling, C E. et al., Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N. Engl. J. Med. 2021. 384: 1800-1809.
Ortega, H., Lemiere, C., Llanos, J. P., Forshag, M., Price, R., Albers, F., Yancey, S. et al., Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. Allergy Asthma Clin. Immunol. 2019. 15: 37.
Menzies-Gow, A., Gurnell, M., Heaney, L. G., Corren, J., Bel, E. H., Maspero, J., Harrison, T. et al., Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir. Med. 2022. 10: 47-58.
Moore, W. C., Kornmann, O., Humbert, M., Poirier, C., Bel, E. H., Kaneko, N., Smith, S G. et al., Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur. Respir. J. 2022. 59: 2100396.
Carsin, A., Mazenq, J., Ilstad, A., Dubus, J. C., Chanez, P. and Gras, D., Bronchial epithelium in children: a key player in asthma. Eur. Respir. Rev. 2016. 25: 158-169.
Saglani, S., Malmstrom, K., Pelkonen, A. S., Malmberg, L. P., Lindahl, H., Kajosaari, M., Turpeinen, M. et al., Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am. J. Respir. Crit. Care Med. 2005. 171: 722-727.
Reynolds, C. D., Nolan, S. O., Huebschman, J. L., Hodges, S. L. and Lugo, J. N., Early-life status epilepticus acutely impacts select quantitative and qualitative features of neonatal vocalization behavior: spectrographic and temporal characterizations in C57BL/6 mice. Epilepsy Behav. 2017. 72: 58-62.
Arrieta, M. C., Stiemsma, L. T., Dimitriu, P. A., Thorson, L., Russell, S., Yurist-Doutsch, S., Kuzeljevic, B. et al., Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 2015. 7: 307ra152.
de Kleer, I. M., Kool, M., de Bruijn, M. J., Willart, M., van Moorleghem, J., Schuijs, M. J., Plantinga, M. et al., Perinatal activation of the interleukin-33 pathway promotes type 2 immunity in the developing lung. Immunity 2016. 45: 1285-1298.
Yancey, S. W., Ortega, H. G., Keene, O. N. and Bradford, E. S., Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma. Allergy Asthma Clin. Immunol. 2019. 15: 53.
Hartl, S., Breyer, M. K., Burghuber, O. C., Ofenheimer, A., Schrott, A., Urban, M. H., Agusti, A. et al., Blood eosinophil count in the general population: typical values and potential confounders. Eur. Respir. J. 2020. 55: 1901874.
Saglani, S., Bush, A., Carroll, W., Cunningham, S., Fleming, L., Gaillard, E., Gupta, A. et al., Biologics for paediatric severe asthma: trick or TREAT? Lancet Respir Med. 2019. 7: 294-296.
Jackson, D. J., Bacharier, L. B., Gergen, P. J., Gagalis, L., Calatroni, A., Wellford, S., Gill, M. A. et al., Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022. 400: 502-511.
Teach, S. J., Gill, M. A., Togias, A., Sorkness, C. A., Arbes S. J., Jr., Calatroni, A., Wildfire, J. J. et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J. Allergy Clin. Immunol. 2015. 136: 1476-1485.
Esquivel, A., Busse, W. W., Calatroni, A., Togias, A. G., Grindle, K. G., Bochkov, Y. A., Gruchalla, R S. et al., Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am. J. Respir. Crit. Care Med. 2017. 196: 985-992.
Maspero, J. F., FitzGerald, J. M., Pavord, I. D., Rice, M. S., Maroni, J., Rowe, P. J., Pirozzi, G. et al., Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy 2021. 76: 2621-2624.
Busse, W. W., Maspero, J. F., Rabe, K. F., Papi, A., Wenzel, S. E., Ford, L. B., Pavord, I D. et al., Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv. Ther. 2018. 35: 737-748.
Bacharier, L. B., Maspero, J. F., Katelaris, C. H., Fiocchi, A. G., Gagnon, R., de Mir, I., Jain, N. et al., Dupilumab in children with uncontrolled moderate-to-severe asthma. N. Engl. J. Med. 2021. 385: 2230-2240.
Chachi, L., Diver, S., Kaul, H., Rebelatto, M. C., Boutrin, A., Nisa, P., Newbold, P. et al., Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. Eur. Respir. J. 2019. 54: 1900930.
Godar, M., Deswarte, K., Vergote, K., Saunders, M., de Haard, H., Hammad, H., Blanchetot, C. et al., A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J. Allergy Clin. Immunol. 2018. 142: 1185-1193 e4.
Conde, E., Bertrand, R., Balbino, B., Bonnefoy, J., Stackowicz, J., Caillot, N., Colaone, F. et al., Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice. Nat. Commun. 2021. 12: 2574.
Lloyd, C. M. and Snelgrove, R. J., Type 2 immunity: expanding our view. Sci Immunol 2018. 3: eaat1604.